Gwendolyn Hoben1, Ying Yan1, Nisha Iyer2, Piyaraj Newton1, Dan A Hunter1, Amy M Moore1, Shelly E Sakiyama-Elbert3, Matthew D Wood1, Susan E Mackinnon1. 1. Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, Campus Box 8238, 660 South Euclid Avenue, St. Louis, MO 63110 USA. 2. Department of Biomedical Engineering, Washington University, Campus Box 1097, One Brookings Drive, St. Louis, MO 63130 USA. 3. Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, Campus Box 8238, 660 South Euclid Avenue, St. Louis, MO 63110 USA ; Department of Biomedical Engineering, Washington University, Campus Box 1097, One Brookings Drive, St. Louis, MO 63130 USA.
Abstract
BACKGROUND: Individual contributions of exogenous Schwann cells (SCs) and vascular endothelial growth factor (VEGF) were evaluated in acellular nerve allografts (ANAs). ANA processing removes SCs and vasculature, likely contributing to reduced regeneration compared to autografts. Exogenous SCs may improve the regenerative microenvironment, and VEGF has been shown to stimulate angiogenesis. Replacing these components in ANAs may improve regeneration. METHODS: A rat sciatic nerve transection model was used to study 20-mm grafts. Four graft types were studied: (1) isograft, (2) ANA, (3) ANA-SCs, and (4) ANA-VEGF. After 10 weeks in vivo, the midgraft and distal nerve to the grafts were analyzed for axonal regeneration using histomorphometry to assess total myelinated axon counts, density, width, and percent neural tissue. RESULTS: The most axons in the distal nerve were regenerated in the isograft followed by the ANA- SC group, with 9171 ± 1822 and 7103 ± 1576 regenerated axons respectively. Both the ANA and ANA-VEGF groups had significantly fewer regenerated axons compared to the isograft (p < 0.05) with 5225 ± 2994 and 5709 ± 2657 regenerated axons, respectively. The ANA and ANA-VEGF groups also had significantly reduced fiber density and percent nerve compared to the isograft; the isograft and ANA-SC groups were not significantly different (p < 0.05). CONCLUSIONS: These results show that SCs improve axonal regeneration in a 20 mm ANA to a greater extent than VEGF. VEGF treatment showed a trend toward increased axonal regeneration but was not significantly different compared to the untreated ANA. The role of VEGF may be clearer in longer grafts where ischemia is a greater factor.
BACKGROUND: Individual contributions of exogenous Schwann cells (SCs) and vascular endothelial growth factor (VEGF) were evaluated in acellular nerve allografts (ANAs). ANA processing removes SCs and vasculature, likely contributing to reduced regeneration compared to autografts. Exogenous SCs may improve the regenerative microenvironment, and VEGF has been shown to stimulate angiogenesis. Replacing these components in ANAs may improve regeneration. METHODS: A rat sciatic nerve transection model was used to study 20-mm grafts. Four graft types were studied: (1) isograft, (2) ANA, (3) ANA-SCs, and (4) ANA-VEGF. After 10 weeks in vivo, the midgraft and distal nerve to the grafts were analyzed for axonal regeneration using histomorphometry to assess total myelinated axon counts, density, width, and percent neural tissue. RESULTS: The most axons in the distal nerve were regenerated in the isograft followed by the ANA- SC group, with 9171 ± 1822 and 7103 ± 1576 regenerated axons respectively. Both the ANA and ANA-VEGF groups had significantly fewer regenerated axons compared to the isograft (p < 0.05) with 5225 ± 2994 and 5709 ± 2657 regenerated axons, respectively. The ANA and ANA-VEGF groups also had significantly reduced fiber density and percent nerve compared to the isograft; the isograft and ANA-SC groups were not significantly different (p < 0.05). CONCLUSIONS: These results show that SCs improve axonal regeneration in a 20 mm ANA to a greater extent than VEGF. VEGF treatment showed a trend toward increased axonal regeneration but was not significantly different compared to the untreated ANA. The role of VEGF may be clearer in longer grafts where ischemia is a greater factor.
Authors: Ida K Fox; Kate E Schwetye; Jason D Keune; Michael J Brenner; Jeffrey W Yu; Daniel A Hunter; Patrick M Wood; Susan E Mackinnon Journal: Microsurgery Date: 2005 Impact factor: 2.425
Authors: Amy M Moore; Matthew MacEwan; Katherine B Santosa; Kristofer E Chenard; Wilson Z Ray; Daniel A Hunter; Susan E Mackinnon; Philip J Johnson Journal: Muscle Nerve Date: 2011-06-09 Impact factor: 3.217
Authors: Nithya J Jesuraj; Katherine B Santosa; Matthew R Macewan; Amy M Moore; Rahul Kasukurthi; Wilson Z Ray; Eric R Flagg; Daniel A Hunter; Gregory H Borschel; Philip J Johnson; Susan E Mackinnon; Shelly E Sakiyama-Elbert Journal: Muscle Nerve Date: 2013-11-22 Impact factor: 3.217
Authors: Elizabeth L Whitlock; Sami H Tuffaha; Janina P Luciano; Ying Yan; Daniel A Hunter; Christina K Magill; Amy M Moore; Alice Y Tong; Susan E Mackinnon; Gregory H Borschel Journal: Muscle Nerve Date: 2009-06 Impact factor: 3.217
Authors: M W Laschke; M Rücker; G Jensen; C Carvalho; R Mülhaupt; N-C Gellrich; M D Menger Journal: J Biomed Mater Res A Date: 2008-05 Impact factor: 4.396
Authors: Louis H Poppler; Xueping Ee; Lauren Schellhardt; Gwendolyn M Hoben; Deng Pan; Daniel A Hunter; Ying Yan; Amy M Moore; Alison K Snyder-Warwick; Sheila A Stewart; Susan E Mackinnon; Matthew D Wood Journal: Tissue Eng Part A Date: 2016-07-07 Impact factor: 3.845
Authors: Ying Yan; Daniel A Hunter; Lauren Schellhardt; Xueping Ee; Alison K Snyder-Warwick; Amy M Moore; Susan E Mackinnon; Matthew D Wood Journal: Muscle Nerve Date: 2017-06-06 Impact factor: 3.217
Authors: Travis A Prest; Eric Yeager; Samuel T LoPresti; Emilija Zygelyte; Matthew J Martin; Longying Dong; Alexis Gibson; Oluyinka O Olutoye; Bryan N Brown; Jonathan Cheetham Journal: J Biomed Mater Res A Date: 2017-10-23 Impact factor: 4.396